Servier Bio-innovation Llc

This study tests a new drug called S095029 combined with pembrolizumab in people with advanced stomach or gastro-esophageal junction cancer that has a specific genetic feature (MSI-H/dMMR). The goal is to see if the combination is safe and can shrink tumors. About 48 adults will …

This study tests whether adding a second immunotherapy drug to the standard drug cemiplimab works better for advanced lung cancer with high PD-L1. About 102 adults who have not had prior treatment will receive one of three combinations. The goal is to find safe doses and see if t…